BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2907453)

  • 1. Effects of pretreatment with the retinoid N-(4-hydroxyphenyl)-all-trans-retinamide and phenobarbital on the disposition and metabolism of N-(4-hydroxyphenyl)-all-trans-retinamide in mice.
    Hultin TA; McCormick DL; May CM; Moon RC
    Drug Metab Dispos; 1988; 16(6):783-8. PubMed ID: 2907453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution and metabolism of the retinoid, N-(4-methoxyphenyl)-all-trans-retinamide, the major metabolite of N-(4-hydroxyphenyl)-all-trans-retinamide, in female mice.
    Hultin TA; Filla MS; McCormick DL
    Drug Metab Dispos; 1990; 18(2):175-9. PubMed ID: 1971569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-(4-hydroxyphenyl)-all-trans-retinamide pharmacokinetics in female rats and mice.
    Hultin TA; May CM; Moon RC
    Drug Metab Dispos; 1986; 14(6):714-7. PubMed ID: 2877832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of phenobarbital, 3-methylcholanthrene, and retinoid pretreatment on disposition of orally administered retinoids in mice.
    Kalin JR; Wells MJ; Hill DL
    Drug Metab Dispos; 1984; 12(1):63-7. PubMed ID: 6141914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biotransformation and biological activity of N-(4-hydroxyphenyl)retinamide derivatives in rodents.
    Swanson BN; Newton DL; Roller PP; Sporn MB
    J Pharmacol Exp Ther; 1981 Dec; 219(3):632-7. PubMed ID: 6170750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liquid chromatography method for quantifying N-(4-hydroxyphenyl)retinamide and N-(4-methoxyphenyl)retinamide in tissues.
    Vratilova J; Frgala T; Maurer BJ; Patrick Reynolds C
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Sep; 808(2):125-30. PubMed ID: 15261805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites.
    Sabichi AL; Xu H; Fischer S; Zou C; Yang X; Steele VE; Kelloff GJ; Lotan R; Clifford JL
    Clin Cancer Res; 2003 Oct; 9(12):4606-13. PubMed ID: 14555536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoprevention of skin carcinogenesis by phenylretinamides: retinoid receptor-independent tumor suppression.
    Xu H; Cheepala S; McCauley E; Coombes K; Xiao L; Fischer SM; Clifford JL
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):969-79. PubMed ID: 16467112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of N-(4-hydroxyphenyl)-all-trans-retinamide in rats.
    Swanson BN; Zaharevitz DW; Sporn MB
    Drug Metab Dispos; 1980; 8(3):168-72. PubMed ID: 6104581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of N-(4-hydroxyphenyl)retinamide supplementation on vitamin A metabolism.
    Lewis KC; Zech LA; Phang JM
    Cancer Res; 1994 Aug; 54(15):4112-7. PubMed ID: 8033144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retinoid metabolism in the prostate: effects of administration of the synthetic retinoid N-(4-hydroxyphenyl)retinamide.
    Lewis KC; Hochadel JF
    Cancer Res; 1999 Dec; 59(23):5947-55. PubMed ID: 10606240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex.
    Maurer BJ; Kalous O; Yesair DW; Wu X; Janeba J; Maldonado V; Khankaldyyan V; Frgala T; Sun BC; McKee RT; Burgess SW; Shaw WA; Reynolds CP
    Clin Cancer Res; 2007 May; 13(10):3079-86. PubMed ID: 17505011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced inhibition of mammary carcinogenesis by combined treatment with N-(4-hydroxyphenyl)retinamide and ovariectomy.
    McCormick DL; Mehta RG; Thompson CA; Dinger N; Caldwell JA; Moon RC
    Cancer Res; 1982 Feb; 42(2):508-12. PubMed ID: 6459843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of N-(4-hydroxyphenyl)retinamide on murine mammary tumor cells in culture.
    Bunk MJ; Telang NT; Higgins PJ; Traganos F; Sarkar NH
    Nutr Cancer; 1985; 7(1-2):105-15. PubMed ID: 2999720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets β-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Δ4-desaturase 1.
    Poliakov E; Samuel W; Duncan T; Gutierrez DB; Mata NL; Redmond TM
    PLoS One; 2017; 12(4):e0176487. PubMed ID: 28448568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of the chemopreventive retinoid N-(4-hydroxyphenyl)retinamide by mammary gland in organ culture.
    Mehta RG; Hultin TA; Moon RC
    Biochem J; 1988 Dec; 256(2):579-84. PubMed ID: 2851995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide.
    Sabichi AL; Modiano MR; Lee JJ; Peng YM; Xu MJ; Villar H; Dalton WS; Lippman SM
    Clin Cancer Res; 2003 Jul; 9(7):2400-5. PubMed ID: 12855611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative activity of dietary or topical exposure to three retinoids in the promotion of skin tumor induction in mice.
    McCormick DL; Bagg BJ; Hultin TA
    Cancer Res; 1987 Nov; 47(22):5989-93. PubMed ID: 2959358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-(4-hydroxyphenyl)retinamide (Fenretinide) in combination with retinoic acid enhances differentiation and retinoylation of proteins.
    Takahashi N; Sausville EA; Breitman TR
    Clin Cancer Res; 1995 Jun; 1(6):637-42. PubMed ID: 9816026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acitretin elimination in Sprague-Dawley rats pretreated with phenobarbital or beta-naphthoflavone.
    Small DS; McNamara PJ
    Drug Metab Dispos; 1995 Apr; 23(4):465-72. PubMed ID: 7600913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.